The biosimilars pipeline of the South Korean company Samsung Bioepis would be highly impressive if it belonged to a long-established, world-leading pharma giant.
As well as having received European approval for biosimilars of etanercept and infliximab, two of the three top-selling arthritis drugs in the world, it also has strong Phase III data supporting a version of the biggest seller of them all – AbbVie’s (NYSE: ABBV) Humira (adalimumab).
That is just in rheumatology, with Samsung Bioepis’ pipeline of 13 biosimilars molecules also including encouraging agents in diabetes and oncology.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze